Question 1

What is ICD-10 code R97.20?

Accepted Answer

R97.20 is the ICD-10-CM diagnosis code for elevated prostate specific antigen [psa]. A blood test shows elevated prostate specific antigen (PSA), a protein produced by the prostate that may indicate prostate cancer or other prostate conditions. R97.20 sits in the ICD-10-CM chapter for symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (r00-r99), within the section covering abnormal tumor markers (r97).

R97.20 is a billable ICD-10-CM code but does not map to a payment HCC under the CMS-HCC V28, V24, ESRD, or RxHCC risk adjustment models. It can be reported on Medicare Advantage encounter data submissions but it does not contribute to a beneficiary's RAF score and therefore does not affect risk-adjusted payments to the plan.

Elevated PSA alone does not confirm prostate cancer; document whether biopsy or imaging was performed.

Question 2

Is R97.20 an HCC code?

Accepted Answer

No. R97.20 is a billable ICD-10-CM code but does not map to any payment HCC category under the CMS-HCC V28, V24, ESRD, or RxHCC risk adjustment models. It can still be reported on Medicare Advantage encounter data submissions, but it does not contribute to the beneficiary's Risk Adjustment Factor (RAF) score and therefore does not affect the risk-adjusted capitation payment to the plan. V28 reached 100% phase-in for payment year 2026.

Question 3

Is R97.20 billable?

Accepted Answer

Yes. R97.20 is a billable ICD-10-CM code that can be reported on professional and institutional claims as a primary or secondary diagnosis when the provider documentation supports the specific condition described. Billable codes in ICD-10-CM are coded to the highest level of specificity available for the documented diagnosis. R97.20 is current for fiscal year 2026 and remains in the active CMS ICD-10-CM code set published by the National Center for Health Statistics.

Question 4

What is the V28 vs V24 difference for R97.20?

Accepted Answer

R97.20 does not map to a payment HCC under either the CMS-HCC V28 risk adjustment model or the older V24 model. V28 reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition. Because neither model rewards R97.20 with a risk adjustment factor, it contributes zero to a Medicare Advantage beneficiary's RAF score in either version. Coders should check whether provider documentation supports a more specific child code that does map to a payment HCC.

Question 5

What should coders know when reporting R97.20?

Accepted Answer

Elevated PSA alone does not confirm prostate cancer; document whether biopsy or imaging was performed Use with prostate cancer codes (C61) only if malignancy is confirmed

R97.20

Is R97.20 an HCC code?

What This Code Means

Coding Tips

Code Hierarchy

Open R97.20 in the Interactive Encoder